CERo Therapeutics regains Nasdaq minimum bid price compliance, moves to Capital Market

CERO THERAPEUTICS HOLDINGS, INC.

Received Nasdaq confirmation of compliance with Bid Price Requirement on Feb 12, 2025.
Common stock transferred to Nasdaq Capital Market per Nasdaq Panel's extension conditions.
Extension granted until April 22, 2025; company working toward remaining conditions.

item 8.01

CERO THERAPEUTICS HOLDINGS, INC. filing history →

Source: SEC EDGAR

accession 0001213900-25-012891

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.